Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Trial of Maridebart Cafraglutide in Obesity or Overweight With Type 2 Diabetes Mellitus
NCT07684144Phase 3Recruiting
- Sponsor
- Amgen
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Countries
- 5
01
Overview
A Phase 3 trial of maridebart cafraglutide in obesity, type 2 diabetes mellitus (T2DM), sponsored by Amgen. Started Jul 2026; status: recruiting.
02
Drugs
maridebart cafraglutide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07684144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07684144.